



This Trading Floor Research report contains:

Brazil BUY Signal & Cancer-Related Biotechs Surge (Market Update)

A Weekly Follow-up of current stock positions

Market Update

The **Brazilian stock market** started the week with a YTD loss of -5.3%, but yesterday, the MSCI Brazil Index confirmed a buy signal. Leadership stocks started emerging, including **Nu Holdings Ltd. (NU)**, a Brazilian Bank, and **Zenvia CL A (ZENV)**, a cloud-based communications platform stock I purchased yesterday.

The accumulation on ZENV is substantial, indicated by a phenomenal Up/Down Volume Ratio of 9.35. Anything above 1 means more buyers than sellers. 935% more buyers point to stock under massive accumulation.


The buy signal in the Brazilian market opens the door for Zenvia CL A (ZENV) to move higher.

Cancer-related Biotechs continue to show substantial strength.

In less than two hours, Vincerx Pharma Inc. (VINC) achieved all three of my Fibonacci targets, and I sold the position with a 19.6%, 34.6%, and 57.1% gain. Yesterday, I also sold 1/2 the position of the cancer-related Biotech Y-mAbs Therapeutics (YMAB) that I purchased last Wednesday with a 13.8% return.

Today I bought XBiotech Inc. (XBIT) and sold 1/3 of my shares with a 10.3% gain. In after-hours trading, shares are at 7.35, up 20.9% from my purchase.

Biotechs continue to be the strongest group in the market, and cancer-related Biotechs are the strongest of the strongest. More Biotechs are setting up and I anticipate more opportunities soon.





This Trading Floor Research report is the weekly follow-up:

(Please, watch this list closely. If a TFR recommended stock does not appear in this list, it has been sold or was never bought)

- Verano Holdings Corp. (VRNOF) was purchased on February 01 @ 6.13. Shares rallied 15% in the first two days and have sold off, holding above Fibonacci support at 5.81. Today, shares closed at 5.90.
- FAT Brands Inc. (FAT) was purchased on February 01 @ 8.13. I have sold 2/3s of my position at the first two Fibonacci targets, locking in a 9% and 16% gain. The shares are preparing for the next push higher. Closing above Fibonacci resistance at 9.43 should send shares to the next target at 10.00.
- **ProShares UltraShort Utilities (SDP) was purchased on February 05 @ 13.66**. SDP hit its first Fibonacci number at 14.31, and I sold ½ the position with a 4.8% gain.



This Trading Floor Research report is the weekly follow-up:

(Please, watch this list closely. If a TFR recommended stock does not appear in this list, it has been sold or was never bought)

- Tyra Biosciences (TYRA) was purchased yesterday, February 12 @ 19.21. TYRA continues to show tremendous
 relative strength and strong accumulation. The strong accumulation indicates higher prices. Shares closed slightly
 above my purchase price at 19.23.
- **Y-mAbs Therapeutics Inc. (YMAB) was purchased on February 14 @ 14.88**. On Tuesday, YMAB hit its first Fibonacci target, and I sold ½ of my shares at 17.11 with a 13.8% gain.
- Vincerx Pharma Inc. was purchased on February 20 @ 1.82. Cancer-related Biotechs continue to show substantial strength. In less than two hours, Vincerx Pharma Inc. (VINC) achieved all three of my Fibonacci targets, and I sold the position with a 19.6%, 34.6%, and 57.1% gain.




This Trading Floor Research report is the weekly follow-up:

(Please, watch this list closely. If a TFR recommended stock does not appear in this list, it has been sold or was never bought)

- Zenvia Inc. (ZENV) was purchased on February 20 @ 2.10. The Brazilian stock market started the week with a YTD loss of -5.3%, but yesterday, the MSCI Brazil Index confirmed a buy signal. Leadership stocks started emerging, including Nu Holdings Ltd. (NU), a Brazilian Bank, and Zenvia CL A (ZENV), a cloud-based communications platform stock I purchased yesterday. The accumulation on ZENV is substantial, indicated by a phenomenal Up/Down Volume Ratio of 9.35. Anything above 1 means more buyers than sellers. 935% more buyers point to stock under massive accumulation. The buy signal in the Brazilian market opens the door for Zenvia CL A (ZENV) to move higher.
- XBiotech Inc. (XBIT) was purchased today, February 21 @ 6.08. The stock moved quickly to its first Fibonacci target at 6.69, where I sold 1/3 of my shares with a 10.3% gain. In after-hours trading, shares are at 7.35, up 20.9% from my purchase. XBIT is approaching its second Fibonacci target at 7.49.






The results are not (or may not be) representative of the performance of all selections made by Trading Floor Research (TFR) newsletter.

We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. TFR is providing information on this resource to you subject to the TFR "Terms and Conditions of Service" disclaimer.

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice.





Disclaimer

Before using this site, please make sure that you note the following important information:

Do your Own Research

Our content is intended to be used and must be used for informational purposes only. It is very important to do your own analysis before making any investment based on your own personal circumstances. You should take independent financial advice from a professional in connection with, or independently research and verify, any information that you find on our Website and wish to rely upon, whether for the purpose of making an investment decision or otherwise.

The content of this email is confidential and intended for the recipient specified in message only. It is strictly forbidden to share any part of this message with any third party, without a written consent of the sender. If you received this message by mistake, please reply to this message and follow with its deletion, so that we can ensure such a mistake does not occur in the future